Mast Cell Tumors

Withrow and MacEwen's Small Animal Clinical Oncology: Fifth Edition

Volumn , Issue , 2012, Pages 335-355

  London, Cheryl A ^a   Thamm, Douglas H ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901904138     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2362-5.00020-7     Document Type: Chapter

References (254)

1. Bostock DE Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1986, 142:1-19.
2. Carpenter JL, Andrews LK, Holzworth J Tumors and tumor-like lesions. Diseases of the cat: medicine and surgery 1987, WB Saunders, Philadelphia. J. Holzworth (Ed.).
3. Finnie JW, Bostock DE Skin neoplasia in dogs. Aust Vet J 1979, 55:602-604.
4. Miller MA, Nelson SL, Turk JR, et al. Cutaneous neoplasia in 340 cats. Vet Pathol 1991, 28:389-395.
5. Rothwell TL, Howlett CR, Middleton DJ, et al. Skin neoplasms of dogs in Sydney. Aust Vet J 1987, 64:161-164.
6. Kumar V, Sharma A Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol Immunol 2010, 48:14-25.
7. Noviana D, Mamba K, Makimura S, et al. Distribution, histochemical and enzyme histochemical characterization of mast cells in dogs. J Mol Histol 2004, 35:123-132.
8. Metz M, Piliponsky AM, Chen CC, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006, 313:526-530.
9. Lin TY, London CA A functional comparison of canine and murine bone marrow derived cultured mast cells. Vet Immunol Immunopathol 2006, 114:320-334.
10. Lin TY, Rush LJ, London CA Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol 2006, 113:37-52.
11. Lin TY, London CA Characterization and modulation of canine mast cell derived eicosanoids. Vet Immunol Immunopathol 2010, 135:118-127.
12. Brodey RS Canine and feline neoplasia. Adv Vet Sci Comp Med 1970, 14:309-354.
13. Brodey RS, Riser WH Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop 1969, 62:54-64.
14. Patnaik AK, Ehler WJ, MacEwen EG Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984, 21:469-474.
15. Peters JA Canine mastocytoma: excess risk as related to ancestry. J Natl Cancer Inst 1969, 42:435-443.
16. White CR, Hohenhaus AE, Kelsey J, et al. Cutaneous MCTs: Associations with spay/neuter status, breed, body size, and phylogenetic cluster. J Am Anim Hosp Assoc 2011, 47:210-216.
17. McNiel EA, Prink AL, O'Brien TD Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol 2004, 4:2-8.
18. Davis BJ, Page R, Sannes PL, et al. Cutaneous mastocytosis in a dog. Vet Pathol 1992, 29:363-365.
19. Dunn TB, Patter H A transplantable mast cell neoplasm in the mouse. J Natl Cancer Inst 1957, 18:587-601.
20. Hottendorf GH, Nielsen SW Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl Veterinarmed A 1967, 14:272-281.
21. Peterson SL Scar-associated canine mast cell tumor. Canine Pract 1985, 12:23-29.
22. Bowles CA, Kerber WT, Rangan SRS, et al. Characterization of a transplantable, canine, immature mast cell tumor. Cancer Res 1972, 32:1434-1441.
23. Lombard LS, Moloney JB Experimental transmission of mast cell sarcoma in dogs. Fed Proc 1959, 18:490-495.
24. Nielson SW, Cole CR Homologous transplantation of canine neoplasms. Am J Vet Res 1961, 27:663-672.
25. Stone JM, Jacky PB, Prieur DJ Chromosomal fragile site expression in boxer dogs with mast cell tumors. Am J Med Genetics 1991, 40:223-229.
26. Ginn PE, Fox LE, Brower JC, et al. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet Pathol 2000, 37:33-39.
27. Jaffe MH, Hosgood G, Taylor HW, et al. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet Pathol 2000, 37:40-46.
28. Ozaki K, Yamagami T, Nomura K, et al. Mast cell tumors of the gastrointestinal tract in 39 dogs. Vet Pathol 2002, 39:557-564.
29. Mayr B, Reifinger M, Brem G, et al. Cytogenetic, ras, and p53: studies in cases of canine neoplasms (hemangiopericytoma, mastocytoma, histiocytoma, chloroma). J Hered 1999, 90:124-128.
30. Wu H, Hayashi T, Inoue M Immunohistochemical expression of p27 and p21 in canine cutaneous mast cell tumors and histiocytomas. Vet Pathol 2004, 41:296-299.
31. Elling H, Ungemach FR Sexual hormone receptors in canine mast cell tumour cytosol. J Comp Pathol 1982, 92:629-630.
32. Macy DW Canine and feline mast cell tumors: Biologic behavior, diagnosis, and therapy. Sem Vet Med Surg (Sm Anim) 1986, 1:72-83.
33. Gerritsen RJ, Teske E, Kraus JS, et al. Multi-agent chemotherapy for mast cell tumours in the dog. Vet Q 1998, 20:28-31.
34. Galli SJ, Zsebo KM, Geissler EN The kit ligand, stem cell factor. Adv Immunol 1994, 55:1-95.
35. Roskoski R Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 338:1307-1315.
36. Roskoski R Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 337:1-13.
37. Kiupel M, Webster JD, Kaneene JB, et al. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol 2004, 41:371-377.
38. London CA, Kisseberth WC, Galli SJ, et al. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 1996, 115:399-414.
39. Morini M, Bettini G, Preziosi R, et al. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. J Histochem Cytochem 2004, 52:705-708.
40. Reguera MJ, Rabanal RM, Puigdemont A, et al. Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 2000, 22:49-54.
41. Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002, 63:1718-1723.
42. Jones CL, Grahn RA, Chien MB, et al. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 2004, 16:95-100.
43. Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008, 6:1137-1145.
44. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999, 27:689-697.
45. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003, 9:2755-2768.
46. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006, 8:104-111.
47. Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, et al. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res 2008, 4:32.
48. Zemke D, Yamini B, Yuzbasiyan-Gurkan V Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002, 39:529-535.
49. Bostock DE The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973, 14:27-41.
50. Mullins MN, Dernell WS, Withrow SJ, et al. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc 2006, 228:91-95.
51. Tams TR, Macy DW Canine mast cell tumors. Comp Cont Ed Pract Vet 1981, 27:259-263.
52. Van Pelt DR, Fowler JD, Leighton FA Multiple cutaneous mast cell tumors in a dog: A case report and brief review. Can Vet J 1986, 27:259-263.
53. Cohen D, Reif SS, Brodey RS Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 1974, 34:2859-2868.
54. Thamm DH, Vail DM Mast cell tumors. Small animal clinical oncology 2001, 261-282. WB Saunders, Philadelphia. ed 3. S.J. Withrow, E.G. MacEwen (Eds.).
55. Crowe DT, Goodwin MA, Greene CE Total laryngectomy for laryngeal mast cell tumor in a dog. J Am Anim Hosp Assoc 1986, 22:809-816.
56. Iwata N, Ochiai K, Kadosawa T, et al. Canine extracutaneous mast-cell tumours consisting of connective tissue mast cells. J Comp Pathol 2000, 123:306-310.
57. Moore LE, Garrett LD, Debey B, et al. Spinal mast cell tumor in a dog. J Am Anim Hosp Assoc 2002, 38:67-70.
58. Patnaik AK, MacEwen EG, Black AP, et al. Extracutaneous mast-cell tumor in the dog. Vet Pathol 1982, 19:608-615.
59. Steffey M, Rassnick KM, Porter B, et al. Ureteral mast cell tumor in a dog. J Am Anim Hosp Assoc 2004, 40:82-85.
60. Davies AP, Hayden DW, Klausner JS, et al. Noncutaneous systemic mastocytosis and mast cell leukemia in a dog: case report and literature review. J Am Anim Hosp Assoc 1981, 17:361-368.
61. Lester SL, McGonigle LF, McDonald GK Disseminated anaplastic mastocytoma with terminal mastcythemia in a dog. J Am Anim Hosp Assoc 1981, 17:355-360.
62. Takahashi T, Kadosawa T, Nagase M, et al. Visceral mast cell tumors in dogs: 10 cases (1982-1997). J Am Vet Med Assoc 2000, 216:222-226.
63. O'Keefe DA, Couto CG, Burke-Schwartz C, et al. Systemic mastocytosis in 16 dogs. J Vet Intern Med 1987, 1:75-80.
64. Pollack MJ, Flanders JA, Johnson RC Disseminated malignant mastocytoma in a dog. J Am Anim Hosp Assoc 1991, 27:435-440.
65. Fox LE, Rosenthal RC, Twedt DC, et al. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern Med 1990, 4:242-246.
66. Howard EB, Sawa TR, Nielsen SW, et al. Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Pathol Vet 1969, 6:146-158.
67. Ishiguro T, Kadosawa T, Takagi S, et al. Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. J Vet Intern Med 2003, 17:194-198.
68. Roberts LJ, Sweetman BJ, Lewis RA, et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980, 303:1400-1484.
69. Scott HW, Parris WCV, Sandidge PC, et al. Hazards in operative management of patients with systemic mastocytosis. Ann Surg 1983, 197:507-514.
70. Hottendorf GH, Nielsen SW, Kenyon AJ Canine mastocytoma: I. Blood coagulation time in dogs with mastocytoma. Pathol Vet 1965, 2:129-141.
71. Murphy S, Sparkes AH, Smith KC, et al. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 2004, 154:743-746.
72. Simoes JP, Schoning P, Butine M Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol 1994, 31:637-647.
73. Bostock DE, Crocker J, Harris K, et al. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer 1989, 59:915-918.
74. Michels GM, Knapp DW, DeNicola DB, et al. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc 2002, 38:458-466.
75. Seguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc 2001, 218:1120-1123.
76. Weisse C, Shofer FS, Sorenmo K Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 2002, 38:71-73.
77. Schultheiss PC, Gardiner DW, Rao S, et al. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2011, 238:1464-1469.
78. Hume CT, Kiupel M, Rigatti L, et al. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). J Am Anim Hosp Assoc 2011, 47:37-44.
79. Northrup NC, Harmon BG, Gieger TL, et al. Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest 2005, 17:245-248.
80. Northrup NC, Howerth EW, Harmon BG, et al. Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. J Vet Diagn Invest 2005, 17:561-564.
81. Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011, 48:147-155.
82. Preziosi R, Sarli G, Paltrinieri M Prognostic value of intratumoral vessel density in cutaneous mast cell tumors of the dog. J Comp Pathol 2004, 130:143-151.
83. Abadie JJ, Amardeilh MA, Delverdier ME Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 1999, 215:1629-1634.
84. Scase TJ, Edwards D, Miller J, et al. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 2006, 20:151-158.
85. Seguin B, Besancon MF, McCallan JL, et al. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med 2006, 20(4):933-940.
86. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, et al. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol 2007, 44:298-308.
87. Maglennon GA, Murphy S, Adams V, et al. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours. Vet Comp Oncol 2008, 6:268-274.
88. Ozaki K, Yamagami T, Nomura K, et al. Prognostic significance of surgical margin, Ki-67 and cyclin D1 protein expression in grade II canine cutaneous mast cell tumor. J Vet Med Sci 2007, 69:1117-1121.
89. Sakai H, Noda A, Shirai N, et al. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression. J Comp Pathol 2002, 127:233-238.
90. Thompson JJ, Yager JA, Best SJ, et al. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Vet Pathol 2011, 48:169-181.
91. Kravis LD, Vail DM, Kisseberth WC, et al. Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. J Am Vet Med Assoc 1996, 209:1418-1420.
92. Romansik EM, Reilly CM, Kass PH, et al. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol 2007, 44:335-341.
93. Elston L, Sueiro FA, Cavalcanti J, et al. The importance of the mitotic index as a prognostic factor for canine cutaneous mast cell tumors - a validation study. Vet Pathol 2009, 46:362-365.
94. Preziosi R, Sarli G, Paltrinieri M Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours. Vet Res Commun 2007, 31:287-296.
95. Thompson JJ, Pearl DL, Yager JA, et al. Canine subcutaneous mast cell tumor: characterization and prognostic indices. Vet Pathol 2011, 48:156-168.
96. Ayl RD, Couto CG, Hammer AS, et al. Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumors. Vet Pathol 1992, 29:386-390.
97. Patruno R, Arpaia N, Gadaleta CD, et al. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 2009, 13:555-561.
98. Strefezzi Rde F, Xavier JG, Catao-Dias JL Morphometry of canine cutaneous mast cell tumors. Vet Pathol 2003, 40:268-275.
99. Strefezzi Rde F, Xavier JG, Kleeb SR, et al. Nuclear morphometry in cytopathology: a prognostic indicator for canine cutaneous mast cell tumors. J Vet Diagn Invest 2009, 21:821-825.
100. Webster JD, Kiupel M, Kaneene JB, et al. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol 2004, 41:371-377.
101. Bergman PJ, Craft DM, Newman SJ, et al. Correlation of histologic grading of canine mast cell tumors with Ki67/PCNA/AgNOR/c-Kit scores: 38 cases (2002-2003). Vet Comp Oncol 2004, 2:98.
102. Moriello KA, Rosenthal RC Clinical approach to tumors of the skin and subcutaneous tissues. Vet Clin North Am Small Anim Pract 1990, 20:1163-1190.
103. O'Keefe DA Canine mast cell tumors. Vet Clin North Am Sm Anim Pract 1990, 20:1105-1115.
104. Richardson RC, Rebar AH, Elliott GS Common skin tumors of the dog: A clinical approach to diagnosis and treatment. Comp Cont Ed Pract Vet 1984, 6:1080-1086.
105. Turrel JM, Kitchell BE, Miller LM, et al. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 1988, 193:936-940.
106. Cahalane AK, Payne S, Barber LG, et al. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc 2004, 225:401-408.
107. Sfiligoi G, Rassnick KM, Scarlett JM, et al. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001). J Am Vet Med Assoc 2005, 226:1368-1374.
108. Hillman LA, Garrett LD, de Lorimier LP, et al. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006). J Am Vet Med Assoc 2010, 237:936-942.
109. Gieger TL, Theon AP, Werner JA, et al. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). J Vet Intern Med 2003, 17:687-692.
110. Fife M, Blocker T, Fife T, et al. Canine conjunctival mast cell tumors: a retrospective study. Vet Ophthalmol 2011, 14:153-160.
111. Krick EL, Billings AP, Shofer FS, et al. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol 2009, 7:130-138.
112. Murphy S, Sparkes AH, Blunden AS, et al. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec 2006, 158:287-291.
113. Thamm DH, Mauldin EA, Vail DM Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999, 13:491-497.
114. Thamm DH, Turek MM, Vail DM Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006, 68:581-587.
115. Kiupel M, Webster JD, Miller RA, et al. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. J Vet Med A Physiol Pathol Clin Med 2005, 52:280-286.
116. Zavodovskaya R, Chien MB, London CA Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. J Vet Intern Med 2004, 18:915-917.
117. LaDue T, Price GS, Dodge R, et al. Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound 1998, 39:57-62.
118. Chaffin K, Thrall DE Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet Radiol Ultrasound 2002, 43:392-395.
119. Camps-Palau MA, Leibman NF, Elmslie R, et al. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet Comp Oncol 2007, 5:156-167.
120. Clinkenbeard KD Diagnostic cytology: Mast cell tumors. Comp Cont Ed Pract Vet 1991, 13:1697-1704.
121. Mederle O, Mederle N, Bocan EV, et al. VEGF expression in dog mastocytoma. Rev Med Chir Soc Med Nat Iasi 2010, 114:185-188.
122. Rabanal RH, Fondevila DM, Montane V, et al. Immunocytochemical diagnosis of skin tumours of the dog with special reference to undifferentiated types. Res Vet Sci 1989, 47:129-133.
123. Sandusky GE, Carlton WW, Wightman KA Diagnostic immunohistochemistry of canine round cell tumors. Vet Pathol 1987, 24:495-499.
124. Bookbinder PF, Butt MT, Harvey HJ Determination of the number of mast cells in lymph node, bone marrow, and buffy coat cytologic specimens from dogs. J Am Vet Med Assoc 1992, 200:1648-1650.
125. Sato AF, Solano M Ultrasonographic findings in abdominal mast cell disease: a retrospective study of 19 patients. Vet Radiol Ultrasound 2004, 45:51-57.
126. Stefanello D, Valenti P, Faverzani S, et al. Ultrasound-guided cytology of spleen and liver: a prognostic tool in canine cutaneous mast cell tumor. J Vet Intern Med 2009, 23:1051-1057.
127. Book AP, Fidel J, Wills T, et al. Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors. Vet Radiol Ultrasound 2011, 52:548-554.
128. Hahn KA, Lantz GC, Salisbury SK Comparison of survey radiography with ultrasonography and X-ray computed tomography for clinical staging of subcutaneous neoplasms in dogs. J Am Vet Med Assoc 1990, 196:1795-1798.
129. Cayatte SM, McManus PM, Miller WH, et al. Identification of mast cells in buffy coat preparations from dogs with inflammatory skin diseases. J Am Vet Med Assoc 1995, 206:325-326.
130. McManus PM Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997). J Am Vet Med Assoc 1999, 215:355-357.
131. Stockham SL, Basel DL, Schmidt DA Mastocytemia in dogs with acute inflammatory diseases. Vet Clin Pathol 1986, 15:16-21.
132. Endicott MM, Charney SC, McKnight JA, et al. Clinicopathological findings and results of bone marrow aspiration in dogs with cutaneous mast cell tumours: 157 cases (1999-2002). Vet Comp Oncol 2007, 5:31-37.
133. Plier ML, MacWilliams PS Systemic mastocytosis and mast cell leukemia. Schalm's veterinary hematology 2000, Lippincott Williams & Wilkins, Philadelphia. ed 5. B.F. Feldman, J.G. Zinkl, N.C. Jain (Eds.).
134. Hikasa Y, Morita T, Futaoka Y, et al. Connective tissue-type mast cell leukemia in a dog. J Vet Med Sci 2000, 62:187-190.
135. Simpson AM, Ludwig LL, Newman SJ, et al. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2004, 224:236-240.
136. Fulcher RP, Ludwig LL, Bergman PJ, et al. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2006, 228:210-215.
137. Johnson RE, Sigman JD, Funk GF, et al. Quantification of surgical margin shrinkage in the oral cavity. Head Neck 1997, 19:281-286.
138. Kerns MJ, Darst MA, Olsen TG, et al. Shrinkage of cutaneous specimens: formalin or other factors involved?. J Cutan Pathol 2008, 35:1093-1096.
139. Reimer SB, Seguin B, DeCock HE, et al. Evaluation of the effect of routine histologic processing on the size of skin samples obtained from dogs. Am J Vet Res 2005, 66:500-505.
140. Allan GS, Gilette EL Response of canine mast cell tumors to radiation. J Natl Cancer Inst 1979, 63:691-694.
141. Gillette EL Indications and selection of patients for radiation therapy. Vet Clin North Am Small Anim Pract 1974, 4:889-896.
142. Gillette EL Radiation therapy of canine and feline tumors. J Am Anim Hosp Assoc 1976, 12:359-362.
143. Gillette EL Veterinary radiotherapy. J Am Vet Med Assoc 1976, 157:1707-1712.
144. McClelland RB The treatment of mastocytomas in dogs. Cornell Vet 1964, 54:517-519.
145. Dobson J, Cohen S, Gould S Treatment of canine mast cell tumours with prednisolone and radiotherapy. Vet Comp Oncol 2004, 2:132-141.
146. al-Sarraf R, Mauldin GN, Patnaik AK, et al. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. J Vet Intern Med 1996, 10:376-378.
147. Frimberger AE, Moore AS, LaRue SM, et al. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993). J Am Anim Hosp Assoc 1997, 33:320-324.
148. Poirier VJ, Adams WM, Forrest LJ, et al. Radiation therapy for incompletely excised grade II canine mast cell tumors. J Am Anim Hosp Assoc 2006, 42:430-434.
149. Hahn KA, King GK, Carreras JK Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998). J Am Vet Med Assoc 2004, 224:79-82.
150. Hosoya K, Kisseberth WC, Alvarez FJ, et al. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc 2009, 45:14-18.
151. Davies DR, Wyatt KM, Jardine JE, et al. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004, 40:124-130.
152. Misdorp W Incomplete surgery, local immunostimulation, and recurrence of some tumour types in dogs and cats. Vet Q 1987, 9:279-286.
153. Lagoretta RA, Denman DL, Kelley MC, et al. Use of hyperthermia and radiotherapy in treatment of a large mast cell sarcoma in a dog. J Am Vet Med Assoc 1988, 193:1545-1548.
154. Theon AP, Madewell BR, Castro J High dose-rate remote afterloading brachytherapy: Preliminary results in canine and feline cutaneous and subcutaneous tumors. Proc Annu Conf Vet Cancer Soc 1993, 23:109-110.
155. Northrup NC, Roberts RE, Harrell TW, et al. Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004, 40:309-315.
156. Frimberger AE, Moore AS, Cincotta L, et al. Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer. Clin Cancer Res 1998, 4:2207-2218.
157. Tanabe S, Yamaguchi M, Iijima M, et al. Fluorescence detection of a new photosensitizer, PAD-S31, in tumour tissues and its use as a photodynamic treatment for skin tumours in dogs and a cat: a preliminary report. Vet J 2004, 167:286-293.
158. Rogers KS Common questions about diagnosing and treating canine mast cell tumors. Vet Med 1993, 88:246-250.
159. Spugnini EP, Vincenzi B, Baldi F, et al. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res 2006, 26:4585-4589.
160. Spugnini EP, Vincenzi B, Citro G, et al. Evaluation of cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. J Vet Intern Med 2011, 25:407-411.
161. Kodre V, Cemazar M, Pecar J, et al. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo 2009, 23:55-62.
162. Neyens IJ, Kirpensteijn J, Grinwis GC, et al. Pilot study of intraregional deionised water adjunct therapy for mast cell tumours in dogs. Vet Rec 2004, 154:90-91.
163. Grier RL, Di Guardo G, Schaffer CB, et al. Mast cell tumor destruction by deionized water. Am J Vet Res 1990, 51:1116-1120.
164. Grier RL, DiGuardo G, Myers R, et al. Mast cell tumour destruction in dogs by hypotonic solution. J Small Anim Pract 1995, 36:385-388.
165. Jaffe MH, Hosgood G, Kerwin SC, et al. The use of deionized water for the treatment of canine cutaneous mast cell tumors. Vet Cancer Soc Newsl 1998, 22:9-10.
166. Jaffe MH, Hosgood G, Kerwin SC, et al. Deionised water as an adjunct to surgery for the treatment of canine cutaneous mast cell tumours. J Small Anim Pract 2000, 41:7-11.
167. Brocks BA, Neyens IJ, Teske E, et al. Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study. Vet Surg 2008, 37:472-478.
168. Asboe-Hanson G The mast cell: Cortisone action on connective tissue. Proc Soc Exp Biol Med 1952, 80:677-679.
169. Bloom F Effect of cortisone on mast cell tumors (mastocytoma) of the dog. Proc Soc Exp Biol Med 1952, 80:651-654.
170. Brodey RS, McGrath JT, Martin JE Preliminary observations on the use of cortisone in canine mast cell sarcoma. J Am Vet Med Assoc 1953, 123:391-393.
171. Stanclift RM, Gilson SD Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2008, 232:53-62.
172. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994, 8:406-408.
173. Takahashi T, Kadosawa T, Nagase M, et al. Inhibitory effects of glucocorticoids on proliferation of canine mast cell tumor. J Vet Med Sci 1997, 59:995-1001.
174. Matsuda A, Tanaka A, Amagai Y, et al. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells. Vet Immunol Immunopathol 2011, 144:321-328.
175. Rassnick KM, Al-Sarraf R, Bailey DB, et al. Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs. Vet Comp Oncol 2010, 8:103-111.
176. Henry CJ, Downing S, Rosenthal RC, et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res 2007, 68:1246-1251.
177. Valent P, Arock M, Akin C, et al. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood 2010, 116:850-851.
178. Cooper M, Tsai X, Bennett P Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Vet Comp Oncol 2009, 7:196-206.
179. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999, 13:601-605.
180. McCaw DL, Miller MA, Bergman PJ, et al. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 1997, 11:375-378.
181. Grant IA, Rodriguez CO, Kent MS, et al. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 2008, 22:388-393.
182. Taylor F, Gear R, Hoather T, et al. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J Small Anim Pract 2009, 50:284-289.
183. Rassnick KM, Bailey DB, Russell DS, et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet Comp Oncol 2010, 8:138-152.
184. Malone EK, Rassnick KM, Wakshlag JJ, et al. Calcitriol (1, 25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Vet Comp Oncol 2010, 8:209-220.
185. Hayes A, Adams V, Smith K, et al. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet Comp Oncol 2007, 5:168-176.
186. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 2008, 22:1390-1396.
187. Vickery KR, Wilson H, Vail DM, et al. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol 2008, 6:111-119.
188. Singh J, Rana JS, Sood N, et al. Clinico-pathological studies on the effect of different anti-neoplastic chemotherapy regimens on transmissible venereal tumours in dogs. Vet Res Commun 1996, 20:71-81.
189. Ma Y, Longley BJ, Wang X, et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region of canine mast cell neoplasms. J Invest Dermatol 1999, 112:165-170.
190. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
191. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003, 9:5729-5734.
192. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009, 15:3856-3865.
193. Carlsten KS, London CA, Haney S, et al. Multicenter, prospective trial of hypofractionated radiation therapy plus toceranib for unresectable canine mast cell tumors. J Vet Intern Med 2012, 26:135-141.
194. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia) in solid tumours. Vet Comp Oncol Epub ahead of print 2011.
195. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008, 22:1301-1309.
196. Hahn KA, Legendre AM, Shaw NG, et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res 2010, 71:1354-1361.
197. Isotani M, Ishida N, Tominaga M, et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008, 22(4):985-988.
198. Marconato L, Bettini G, Giacoboni C, et al. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med 2008, 22(4):1001-1007.
199. Yamada O, Kobayashi M, Sugisaki O, et al. Imatinib elicited a favorable
200. Robat C, London C, Bunting L, et al. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia) in dogs: a phase I dose-finding study. Vet Comp Oncol Epub ahead of print 2011.
201. Kisseberth WC, Murahari S, London CA, et al. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. Am J Vet Res 2008, 69:938-945.
202. Lin TY, Fenger J, Murahari S, et al. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood 2010, 115:4217-4225.
203. Nagamine MK, Sanches DS, Pinello KC, et al. In vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor. Vet Res Commun 2011, 35:391-399.
204. Lin TY, Bear M, Du Z, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol 2008, 36:1266-1277.
205. London CA, Bear MD, McCleese J, et al. Phase I evaluation of STA-1474, a Prodrug of the novel HSP90 inhibitor Ganetespib, in dogs with spontaneous cancer. PLoS One 2011, 6:e27018.
206. Pinello KC, Nagamine M, Silva TC, et al. In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA). Vet Res Commun Epub ahead of print 2009.
207. Ohashi E, Miyajima N, Nakagawa T, et al. Retinoids induce growth inhibition and apoptosis in mast cell tumor cell lines. J Vet Med Sci 2006, 68:797-802.
208. Miyajima N, Watanabe M, Ohashi E, et al. Relationship between retinoic acid receptor alpha gene expression and growth-inhibitory effect of all-trans retinoic acid on canine tumor cells. J Vet Intern Med 2006, 20:348-354.
209. Elders RC, Baines SJ, Catchpole B Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Vet Immunol Immunopathol 2009, 130:11-16.
210. Peter B, Gleixner KV, Cerny-Reiterer S, et al. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica 2011, 96:672-680.
211. Kenyon AJ, Ramos L, Michaels EB Histamine-induced suppressor macrophage inhibits fibroblast growth and wound healing. Am J Vet Res 1983, 44:2164-2166.
212. Huttunen M, Hyttinen M, Nilsson G, et al. Inhibition of keratinocyte growth in cell culture and whole skin culture by mast cell mediators. Exp Dermatol 2001, 10:184-192.
213. Saar C, Opitz M, Lange W, et al. Mastzellenreitkulose bei katzen. Berl Munch Tierarztl Wochenschr 1969, 82:438-444.
214. Hadzijusufovic E, Peter B, Rebuzzi L, et al. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Vet Immunol Immunopathol 2009, 132:243-250.
215. Isotani M, Tamura K, Yagihara H, et al. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol 2006, 114:168-172.
216. Isotani M, Yamada O, Lachowicz JL, et al. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol 2009, 148:144-153.
217. Mohr FC, Dunston SK Culture and initial characterization of the secretory response of neoplastic cat mast cells. Am J Vet Res 1992, 53:820-828.
218. Antognoni MT, Spaterna A, Lepri E, et al. Characteristic clinical, haematological and histopathological findings in feline mastocytoma. Vet Res Commun 2003, 27(suppl 1):727-730.
219. Feinmehl R, Matus R, Mauldin GN, et al. Splenic mast cell tumors in 43 cats (1975-1992). Proc Annu Conf Vet Cancer Soc 1992, 12:50.
220. Macy DW, Reynolds HA The incidence, characteristics, and clinical management of skin tumors of cats. J Am Anim Hosp Assoc 1981, 17:1026-1034.
221. Buerger RG, Scott DW Cutaneous mast cell neoplasia in cats: 14 cases (1975-1985). J Am Vet Med Assoc 1987, 190:1440-1444.
222. Wilcock BP, Yager JA, Zink MC The morphology and behavior of feline cutaneous mastocytomas. Vet Pathol 1986, 23:320-324.
223. Chastain CB, Turk MA, O'Brien D Benign cutaneous mastocytomas in two litters of Siamese kittens. J Am Vet Med Assoc 1988, 193:959-960.
224. Holzinger EA Feline cutaneous mastocytomas. Cornell Vet 1973, 63:87-93.
225. Litster AL, Sorenmo KU Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J Feline Med Surg 2006, 8:177-183.
226. Molander-McCrary H, Henry CJ, Potter K, et al. Cutaneous mast cell tumors in cats: 32 cases (1991-1994). J Am Anim Hosp Assoc 1998, 34:281-284.
227. Johnson TO, Schulman FY, Lipscomb TP, et al. Histopathology and biologic behavior of pleomorphic cutaneous mast cell tumors in fifteen cats. Vet Pathol 2002, 39:452-457.
228. Garrett LD, Craig CL, Szladovits B, et al. Evaluation of buffy coat smears for circulating mast cells in healthy cats and ill cats without mast cell tumor-related disease. J Am Vet Med Assoc 2007, 231:1685-1687.
229. Skeldon NC, Gerber KL, Wilson RJ, et al. Mastocytaemia in cats: prevalence, detection and quantification methods, haematological associations and potential implications in 30 cats with mast cell tumours. J Feline Med Surg 2010, 12:960-966.
230. Rodriguez-Carino C, Fondevila D, Segales J, et al. Expression of KIT receptor in feline cutaneous mast cell tumors. Vet Pathol 2009, 46:878-883.
231. Fondevila D, Rabanal R, Ferrer L Immunoreactivity of canine and feline mast cell tumors. Schweiz Arch Tierheilk 1990, 132:409-484.
232. Buss MS, Mollander H, Potter K, et al. Predicting survival and prognosis in cats with cutaneous mastocytomas of varying histological grade. Proc Annu Conf Vet Cancer Soc 1996, 16:56-57.
233. Sabattini S, Bettini G Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Vet Pathol 2010, 47:643-653.
234. Montgomery KW, van der Woerdt A, Aquino SM, et al. Periocular cutaneous mast cell tumors in cats: evaluation of surgical excision (33 cases). Vet Ophthalmol 2010, 13:26-30.
235. Lepri E, Ricci G, Leonardi L, et al. Diagnostic and prognostic features of feline cutaneous mast cell tumours: a retrospective analysis of 40 cases. Vet Res Commun 2003, 27(suppl 1):707-709.
236. Turrel JM, Farrelly J, Page RL, et al. Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002). J Am Vet Med Assoc 2006, 228:898-901.
237. Rassnick KM, Gieger TL, Williams LE, et al. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats. J Vet Intern Med 2001, 15:196-199.
238. Rassnick KM, Williams LE, Kristal O, et al. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). J Am Vet Med Assoc 2008, 232:1200-1205.
239. Lachowicz JL, Post GS, Brodsky E A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med 2005, 19:860-864.
240. Bellamy F, Bader T, Moussy A, et al. Pharmacokinetics of masitinib in cats. Vet Res Commun 2009, 33(8):831-837.
241. Daly M, Sheppard S, Cohen N, et al. Safety of masitinib mesylate in healthy cats. J Vet Intern Med 2011, 25:297-302.
242. Spangler WL, Culbertson MR Prevalence and type of splenic diseases in cats: 455 cases (1985-1991). J Am Vet Med Assoc 1992, 201:773-776.
243. Hanson JA, Papageorges M, Girard E, et al. Ultrasonographic appearance of splenic disease in 101 cats. Vet Radiol Ultrasound 2001, 42:441-445.
244. Guerre R, Millet P, Groulade P Systemic mastocytosis in a cat: remission after splenectomy. J Small Anim Pract 1979, 20:769-772.
245. Liska WD, MacEwen EG, Zaki FA, et al. Feline systemic mastocytosis: A review and results of splenectomy in seven cases. J Am Anim Hosp Assoc 1979, 15:589-597.
246. Schulman A Splenic mastocytosis in a cat. California Vet 1987, 17:17-18.
247. Gordon SS, McClaran JK, Bergman PJ, et al. Outcome following splenectomy in cats. J Feline Med Surg 2010, 12:256-261.
248. Bortnowski HB, Rosenthal RC Gastrointestinal mast cell tumors and eosinophilia in two cats. J Am Anim Hosp Assoc 1992, 28:271-275.
249. Halsey CH, Powers BE, Kamstock DA Feline intestinal sclerosing mast cell tumour: 50 cases (1997-2008). Vet Comp Oncol 2010, 8:72-79.
250. Arock M, Valent P Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Exp Rev Hematol 2010, 3:497-516.
251. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
252. Horny HP, Sotlar K, Valent P Mastocytosis: state of the art. Pathobiology 2007, 74:121-132.
253. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
254. Ustun C, Deremer DL, Akin C Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011, 35(9):1143-1152.